Lupin Mandideep facility gets GMP certificate from Japanese agency PMDA

Published On 2019-10-10 04:15 GMT   |   Update On 2019-10-10 04:15 GMT

Pharmaceutical and Medical Devices Agency (PMDA) inspection closed with no critical or major observations. The GMP Certificate issued by the Japanese agency for Mandideep facility (Unit II) is valid till September 2024, it added.


New Delhi: Homegrown pharma major Lupin on Wednesday said it has received GMP Certificate from Pharmaceutical and Medical Devices Agency, Japan for its Mandideep active pharmaceutical ingredients (API) facility.


The GMP (good manufacturing practice) Certificate was issued following an inspection conducted by PMDA between May 14, 2019, and May 17, 2019, Lupin said in a regulatory filing.


Pharmaceutical and Medical Devices Agency (PMDA) inspection closed with no critical or major observations. The GMP Certificate issued by the Japanese agency for Mandideep facility (Unit II) is valid till September 2024, it added.

Also Read: Lupin Mandideep facility red-flagged by USFDA for CGMP violations


Lupin develops and sells a wide range of branded and generic formulations, biotechnology products and APIs globally.


It is a significant player in therapeutic areas of cardiovascular, diabetology, asthma, pediatric, anti-infective and NSAID space among others besides being a global leader in the anti-TB segment.
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News